Benralizumab reduces eosinophils but does not improve eosinophilic gastritis

Treatment with benralizumab induced histological remission, defined as an absence of tissue eosinophilia, among patients with eosinophilic gastritis, according to a study published in The Lancet Gastroenterology & Hepatology.But the persistence of signs, symptoms and biomarkers of the disease during treatment suggested a pathogenic mechanism independent of eosinophil levels in many patients,

Related Keywords

Israel ,Cincinnati ,Ohio ,United States ,Kristen Dowd ,Gastroenterol Hepatol ,Tucker Ellis ,Serpin Pharm ,Byrichard Gawel ,Revolo Biotherapeutics ,Marce Rothenberg ,Food Allergy Fund ,Cincinnati Children Hospital Medical Center ,Bristol Myers Squibb ,International Eosinophil Society ,Astrazeneca ,Israel Binational Grant ,Ception Therapeutics ,Mapi Research Trust ,Pediatric Eosinophilic Esophagitis Symptom Score ,Nextstone One ,Cincinnati Children ,Hospital Medical Center ,Pulmone Therapeutics ,Spoon Guru ,Lancet Gastroenterology ,Lancet Gastroenterol Hepatol ,Dyspepsia Assessment ,Patient Reported Outcome Measurement Information ,